$32.94
-0.60-1.8%
Last update: Nov 10, 1:17 PM
Cogent Biosciences Inc
COGTNASDAQ
Cogent Biosciences rose 3.3% from $32.46 to $33.54, behind the S&P 500's +10.5%. Its worst day was Apr 1 (−8.4%), and its low came Oct 13 at $28.09.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.61 missed the $-0.51 estimate on $0.00 revenue.
+3.0% · S&P 500 +0.2%
Cogent Biosciences shares rose 8.8%, while the S&P 500 rose 2.9%.
+8.8% · S&P 500 +2.9%
Story events cover the past 12 months · Times ET
EPS of $-0.53 beat the $-0.54 estimate on $0.00 revenue.
+0.7% · S&P 500 +0.8%
EPS of $-0.52 beat the $-0.56 estimate on $0.00 revenue.
−2.0% · S&P 500 0.0%
Cogent Biosciences closed at its lowest level of the year, 13.5% below where the year started.
−5.7% · S&P 500 0.0%
EPS of $-0.59 missed the $-0.55 estimate on $0.00 revenue (est. $666,670.00).
+7.0% · S&P 500 +0.3%
Where it ended: a close of $33.54 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 16, 2027 (EPS est. $-0.60, revenue est. $7.4M).
Nothing in the past 12 months.
All COGT dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for COGT and SPY from Benzinga historical bars. Not investment advice.
